Swiss National Bank Buys 6,100 Shares of EXACT Sciences Co. (EXAS)

Swiss National Bank lifted its stake in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 3.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 202,819 shares of the medical research company’s stock after acquiring an additional 6,100 shares during the period. Swiss National Bank’s holdings in EXACT Sciences were worth $10,656,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of EXAS. Dimensional Fund Advisors LP purchased a new stake in shares of EXACT Sciences during the second quarter worth $3,939,000. Stifel Financial Corp increased its position in shares of EXACT Sciences by 16.5% during the second quarter. Stifel Financial Corp now owns 25,023 shares of the medical research company’s stock worth $888,000 after acquiring an additional 3,548 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of EXACT Sciences during the second quarter worth $965,000. The Manufacturers Life Insurance Company increased its position in shares of EXACT Sciences by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 85,270 shares of the medical research company’s stock worth $3,017,000 after acquiring an additional 2,765 shares during the period. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of EXACT Sciences by 68.3% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 19,521 shares of the medical research company’s stock worth $690,000 after acquiring an additional 7,921 shares during the period. 84.88% of the stock is currently owned by institutional investors and hedge funds.

In other EXACT Sciences news, insider Graham Peter Lidgard sold 45,770 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $58.27, for a total value of $2,667,017.90. Following the completion of the transaction, the insider now owns 237,820 shares in the company, valued at $13,857,771.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP D Scott Coward sold 1,665 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total transaction of $87,479.10. Following the completion of the transaction, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The disclosure for this sale can be found here. Insiders sold 630,125 shares of company stock valued at $32,597,655 in the last 90 days. 4.00% of the stock is currently owned by insiders.

EXACT Sciences Co. (NASDAQ EXAS) opened at $48.01 on Wednesday. The company has a quick ratio of 9.98, a current ratio of 10.34 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a 12 month low of $19.91 and a 12 month high of $63.60. The stock has a market cap of $5,850.03, a price-to-earnings ratio of -41.39 and a beta of 0.58.

A number of brokerages recently commented on EXAS. Zacks Investment Research upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research note on Tuesday, January 16th. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. William Blair reiterated a “buy” rating on shares of EXACT Sciences in a research note on Wednesday, January 10th. Goldman Sachs Group began coverage on shares of EXACT Sciences in a research note on Monday, January 29th. They set a “neutral” rating and a $51.00 target price for the company. Finally, Bank of America boosted their target price on shares of EXACT Sciences from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, November 29th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. EXACT Sciences currently has an average rating of “Buy” and a consensus price target of $52.84.

TRADEMARK VIOLATION NOTICE: “Swiss National Bank Buys 6,100 Shares of EXACT Sciences Co. (EXAS)” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/02/21/swiss-national-bank-buys-6100-shares-of-exact-sciences-co-exas.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for EXACT Sciences Co. (NASDAQ:EXAS).

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply